Piper Sandler analyst Yasmeen Rahimi initiated coverage of Soleno Therapeutics with an Overweight rating and $93 price target. The analyst thinks Soleno is undervalued and sees “substantial room for growth,” especially into approval. The firm believes DCCR is de-risked with high approval probability of success for Prader-Willi syndrome, which is an orphan disease with major unmet needs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLNO:
- Soleno Therapeutics Expands Equity Incentive Plan
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Soleno Therapeutics Strengthens Leadership Team with Key Appointments
- Soleno Therapeutics announces appointments to its leadership team
- Soleno Therapeutics initiated with a Buy at Stifel
